• September 1996 - Zyprexa receives FDA approval for schizophrenia
• 2000 – Zyprexa receives FDA approval for bipolar disorder
• May 2002 - Britain's Medicines Control Agency warns that several patients taking Eli Lilly's top selling drug Zyprexa (used to treat schizophrenia) had developed diabetes-related complications. In the Medicine Control Agency's Current Problems newsletter, the regulatory body said that Zyprexa "can adversely affect blood glucose." Forty reports of hyperglycemia (elevated blood sugar), diabetes mellitus, or exacerbation of diabetes have been received in the UK. Four were associated with ketoacidosis and/or coma including one with a fatal outcome.
• April 2002 - The Japanese Health and Welfare Ministry issues an emergency warning to Eli Lilly Japan KK concerning side effects of Zyprexa following the deaths of two diabetic users of the drug. The Ministry said seven other patients had lost consciousness or become comatose after taking the drugs in the previous 10 months.
• 2002 - Study at Duke University showed a connection between Zyprexa and diabetes. This study documented nearly 300 cases of diabetes in people using Zyprexa.
• 2003 - the FDA requested that Eli Lilly and Company update its product labeling for Zyprexa to include a warning about hyperglycemia and diabetes.
• April 11, 2005 – FDA warns that older patients with dementia given Zyprexa at greater risk of dying prematurely
• April 12, 2005 – Black box warning added to Zyprexa label
• June 2005 – Eli Lilly announces plans to settle Zyprexa claims

Atypical antipsychotic medications include: Zyprexa, Symbyax, Seroquel, Risperdal, Abilify, Clozaril, and Geodon. These second generation antipsychotics are intended to help in the management of schizophrenia, acute bipolar mania, and agitation and severe anxiety in people with a wide range of psychotic illnesses. Zyprexa and the other drugs in its class affect a broad range of neurotransmitter receptors and have been shown to have full antipsychotic activity. It has been known now for several years that these medications may increase the risk of diabetes. The FDA asked that manufacturers of all atypical antipsychotics warn about the risk of blood sugar disorders including diabetes mellitus and hyperglycemia. These medications were marketed as having fewer side effects than older antipsychotics like Haldol and Thorazine. However, diabetes and related blood sugar disorders are serious and sometimes fatal side effects that clearly warranted pre-approval testing and patient notification. If you or a loved one took any of the following antipsychotic medications, get a free lawsuit case review today.

• Zyprexa (olanzapine) - Eli Lilly
• Symbyax (olanzapine and fluoxetine HCl) - Eli Lilly
• Risperdal (risperidone)- Johnson & Johnson/Janssen
  Seroquel (quetiapine) – AstraZeneca
• Abilify (aripiprazole) - Bristol-Myers Squibb and Otsuka American Pharmaceutical
• Clozaril (clozapine) – Novartis
• Geodon (ziprasidone) - Pfizer

First Name
Last Name
Email Address
Phone Number
Cell Phone Number
Street Address
Apartment/Suite
City
State
-Choose State- Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington, D.C. West Virginia Wisconsin Wyoming -Other- Zip Code
Date of birth of injured person (mm-dd-yyyy):
Date you started taking Zyprexa
(mm-dd-yyyy):
Date you stopped taking Zyprexa
(mm-dd-yyyy):
Were you diagnosed with diabetes before taking Zyprexa?
Yes
No
Were you diagnosed with diabetes after taking Zyprexa?
Yes
No
Please describe the side effects you experienced:
Other information:
By sumbitting this form I agree to the following disclaimer.